Search Results

There are 2246 results for: content related to: Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics

  1. You have full text access to this OnlineOpen article
    Comparative efficacy of switching to natalizumab in active multiple sclerosis

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 4, April 2015, Pages: 373–387, Timothy Spelman, Tomas Kalincik, Annie Zhang, Fabio Pellegrini, Heinz Wiendl, Ludwig Kappos, Larisa Tsvetkova, Shibeshih Belachew, Robert Hyde, Freek Verheul, Francois Grand-Maison, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Alessandra Lugaresi, Jeannette Lechner-Scott, Celia Oreja-Guevara, Raymond Hupperts, Thor Petersen, Michael Barnett, Maria Trojano, Helmut Butzkueven and on behalf of the MSBase Investigators and the TOP investigators

    Article first published online : 27 FEB 2015, DOI: 10.1002/acn3.180

  2. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience

    Inflammatory Bowel Diseases

    Volume 18, Issue 12, December 2012, Pages: 2203–2208, S.V. Kane, S. Horst, W.J. Sandborn, B. Becker, B. Neis, M. Moscandrew, K.A. Hanson, W.J. Tremaine, D.H. Bruining, W.A. Faubion, D.S. Pardi, W.S. Harmsen, A.R. Zinsmeister and E.V. Loftus

    Article first published online : 14 MAR 2012, DOI: 10.1002/ibd.22943

  3. You have full text access to this OnlineOpen article
    Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b

    Annals of Clinical and Translational Neurology

    Volume 2, Issue 1, January 2015, Pages: 43–55, Jens Ingwersen, Til Menge, Britta Wingerath, Derya Kaya, Jonas Graf, Tim Prozorovski, Andreas Keller, Christina Backes, Markus Beier, Matthias Scheffler, Thomas Dehmel, Bernd C. Kieseier, Hans-Peter Hartung, Patrick Küry and Orhan Aktas

    Article first published online : 5 DEC 2014, DOI: 10.1002/acn3.152

  4. You have free access to this content
    Clinically significant liver injury in patients treated with natalizumab

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 9, May 2010, Pages: 1028–1035, S. BEZABEH, C. M. FLOWERS, C. KORTEPETER and M. AVIGAN

    Article first published online : 16 FEB 2010, DOI: 10.1111/j.1365-2036.2010.04262.x

  5. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

    Annals of Neurology

    Volume 77, Issue 3, March 2015, Pages: 425–435, Tomas Kalincik, Dana Horakova, Tim Spelman, Vilija Jokubaitis, Maria Trojano, Alessandra Lugaresi, Guillermo Izquierdo, Csilla Rozsa, Pierre Grammond, Raed Alroughani, Pierre Duquette, Marc Girard, Eugenio Pucci, Jeannette Lechner-Scott, Mark Slee, Ricardo Fernandez-Bolanos, Francois Grand'Maison, Raymond Hupperts, Freek Verheul, Suzanne Hodgkinson, Celia Oreja-Guevara, Daniele Spitaleri, Michael Barnett, Murat Terzi, Roberto Bergamaschi, Pamela McCombe, Jose Sanchez-Menoyo, Magdolna Simo, Tunde Csepany, Gabor Rum, Cavit Boz, Eva Havrdova, Helmut Butzkueven and on behalf of the MSBase Study Group

    Article first published online : 17 JAN 2015, DOI: 10.1002/ana.24339

  6. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

    Annals of Neurology

    Volume 77, Issue 3, March 2015, Pages: 447–457, Luisa M. Villar, Lucienne Costa-Frossard, Thomas Masterman, Oscar Fernandez, Xavier Montalban, Bonaventura Casanova, Guillermo Izquierdo, Francisco Coret, Hayrettin Tumani, Albert Saiz, Rafael Arroyo, Katharina Fink, Laura Leyva, Carmen Espejo, María Simó-Castelló, María I. García-Sánchez, Florian Lauda, Sara Llufriú, Roberto Álvarez-Lafuente, Javier Olascoaga, Alvaro Prada, Agustín Oterino, Clara de Andrés, Mar Tintoré, Lluis Ramió-Torrentà, Eulalia Rodríguez-Martín, Carmen Picón, Manuel Comabella, Ester Quintana, Eduardo Agüera, Santiago Díaz, Ricardo Fernandez-Bolaños, Juan A. García-Merino, Lamberto Landete, Manuel Menéndez-González, Laura Navarro, Domingo Pérez, Fernando Sánchez-López, Pedro J. Serrano-Castro, Alberto Tuñón, Mercedes Espiño, Alfonso Muriel, Amit Bar-Or and José C. Álvarez-Cermeño

    Article first published online : 30 JAN 2015, DOI: 10.1002/ana.24345

  7. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model

    Neuropathology and Applied Neurobiology

    Darius Häusler, Stefan Nessler, Niels Kruse, Wolfgang Brück and Imke Metz

    Article first published online : 2 MAY 2015, DOI: 10.1111/nan.12220

  8. You have free access to this content
    Monoclonal antibodies in treatment of multiple sclerosis

    Clinical & Experimental Immunology

    Volume 175, Issue 3, March 2014, Pages: 373–384, P. S. Rommer, A. Dudesek, O. Stüve and U.K. Zettl

    Article first published online : 4 FEB 2014, DOI: 10.1111/cei.12197

  9. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study

    European Journal of Neurology

    Volume 19, Issue 5, May 2012, Pages: 783–787, G. Borriello, L. Prosperini, C. Mancinelli, C. Giannì, F. Fubelli and C. Pozzilli

    Article first published online : 7 NOV 2011, DOI: 10.1111/j.1468-1331.2011.03577.x

  10. You have full text access to this OnlineOpen article
    Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 570–577, N. Voloshyna, E. Havrdová, M. Hutchinson, T. Nehrych, X. You, S. Belachew, C. Hotermans and D. Paes

    Article first published online : 15 DEC 2014, DOI: 10.1111/ene.12618

  11. You have free access to this content
    Molecular targeted therapy against the blood–brain barrier in multiple sclerosis

    Clinical and Experimental Neuroimmunology

    Volume 5, Issue s1, December 2014, Pages: 28–34, Takashi Kanda

    Article first published online : 18 DEC 2014, DOI: 10.1111/cen3.12167

  12. You have full text access to this OnlineOpen article
    CD4 cell response to interval therapy with natalizumab

    Annals of Clinical and Translational Neurology

    Regina Berkovich, Daniel M. Togasaki, Steven Y. Cen and Lawrence Steinman

    Article first published online : 6 MAR 2015, DOI: 10.1002/acn3.190

  13. Current Disease-Modifying Treatment of Multiple Sclerosis

    Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine

    Volume 78, Issue 2, March/April 2011, Pages: 161–175, Joy Derwenskus

    Article first published online : 21 MAR 2011, DOI: 10.1002/msj.20239

  14. Therapeutic interference with leukocyte recirculation in multiple sclerosis

    European Journal of Neurology

    Volume 22, Issue 3, March 2015, Pages: 434–442, F. Sellebjerg and P. S. Sørensen

    Article first published online : 13 JAN 2015, DOI: 10.1111/ene.12668

  15. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates

    Inflammatory Bowel Diseases

    Volume 18, Issue 11, November 2012, Pages: 2107–2119, Eric R. Fedyk, Tim Wyant, Li-Li Yang, Vilmos Csizmadia, Kristine Burke, Hua Yang and Vivek J. Kadambi

    Article first published online : 14 MAR 2012, DOI: 10.1002/ibd.22940

  16. You have full text access to this OnlineOpen article
    Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

    Annals of Neurology

    Volume 76, Issue 6, December 2014, Pages: 802–812, Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Schlain, Denise Campagnolo, Shibeshih Belachew and Barry Ticho

    Article first published online : 24 OCT 2014, DOI: 10.1002/ana.24286

  17. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study

    Inflammatory Bowel Diseases

    Volume 18, Issue 8, August 2012, Pages: 1470–1479, Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh, Diane R. Mould, Terry Ponich, Irving Fox and Brian G. Feagan

    Article first published online : 6 DEC 2011, DOI: 10.1002/ibd.21896

  18. Natalizumab discontinuation: an increasingly tricky proposition

    European Journal of Neurology

    Volume 19, Issue 5, May 2012, Pages: 663–664, T. W. West, J. Killestein and R. J. Fox

    Article first published online : 7 NOV 2011, DOI: 10.1111/j.1468-1331.2011.03574.x

  19. You have free access to this content
    Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

    British Journal of Pharmacology

    Volume 166, Issue 3, June 2012, Pages: 823–846, Peter J Bugelski and Pauline L Martin

    Article first published online : 8 MAY 2012, DOI: 10.1111/j.1476-5381.2011.01811.x

  20. You have free access to this content
    Progressive multifocal leukoencephalopathy: Dot-shaped inclusions and virus-host interactions

    Neuropathology

    Yukiko Shishido-Hara

    Article first published online : 6 MAY 2015, DOI: 10.1111/neup.12203